English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18265/20495 (89%)
Visitors : 8354163      Online Users : 1200
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34793


    標題: Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis
    作者: Chen, Jui-Yi
    Pan, Heng-Chih
    Shiao, Chih-Chung
    Chuang, Min-Hsiang
    See, Chun Yin
    Yeh, Tzu-Hsuan
    Yang, Yafei
    Chu, Wen-Kai
    Wu, Vin-Cent
    貢獻者: Chi Mei Med Ctr, Dept Internal Med, Div Nephrol
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    Keelung Chang Gung Mem Hosp, Dept Internal Med, Div Nephrol
    Chang Gung Univ, Coll Med
    Natl Taiwan Univ, Grad Inst Clin Med, Coll Med
    Keelung Chang Gung Mem Hosp, Community Med Res Ctr
    Camillian St Marys Hosp Luodong, Dept Internal Med, Div Nephrol
    St Marys Jr Coll Med Nursing & Management
    Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med ,Div Nephrol
    Everan Hosp, Dept Internal Med, Div Nephrol
    Natl Taiwan Univ Hosp, Dept Internal Med
    Natl Taiwan Univ Hosp, NSARF, Study Grp ARF
    Taiwan Primary Aldosteronism Investigators
    關鍵字: SGLT2 inhibitor
    Diabetes
    Heart failure
    Chronic kidney disease
    Network meta-analysis
    日期: 2023
    上傳時間: 2024-12-25 11:03:33 (UTC+8)
    出版者: BMC
    摘要: BackgroundA comprehensive network meta-analysis comparing the effects of individual sodium-glucose cotransporter 2 (SGLT2) inhibitors on patients with and without comorbidities including diabetes mellitus (DM), heart failure (HF), and chronic kidney disease (CKD) has not been previously conducted.MethodsWe searched PubMed, Embase, Cochrane, and ClinicalTrials.gov for randomized controlled trials up to March 28, 2023. Network meta-analysis using a random-effects model was conducted to calculate risk ratios (RRs). Risk of Bias tool 2.0 was used to assess bias, and CINeMA to assess the certainty of evidence. In the subgroup analysis, the SGLT2 inhibitors were classified into highly (dapagliflozin, empagliflozin, and ertugliflozin) and less selective SGLT2 inhibitors (canagliflozin and sotagliflozin).ResultsA total of fourteen trials with 75,334 patients were analyzed. Among these, 40,956 had taken SGLT2 inhibitors and 34,378 had not. One of the main results with particular findings was empagliflozin users had a significantly lower risk of all-cause death compared to dapagliflozin users in DM population (RR: 0.81, 95% CI 0.69-0.96). In HF population, sotagliflozin users had a borderline significantly lower risk of CV death or hospitalization for HF (HHF) than dapagliflozin users (RR: 0.90, 95% CI 0.80-1.01). In non-HF population, those who used canagliflozin had a significantly lower risk of CV death or HHF compared with those who used dapagliflozin (RR: 0.75, 95% CI 0.58-0.98). At last, for HF patients, those who used less selective SGLT2 inhibitors had a significantly lower risk of MACEs compared to those who used highly selective SGLT2 inhibitors (RR: 0.75, 95% CI 0.62-0.90).ConclusionsOur network meta-analysis revealed that empagliflozin users with diabetes experienced a lower risk of dying from any cause than those using dapagliflozin. Additionally, canagliflozin users demonstrated a reduced risk of cardiovascular death or HHF compared to dapagliflozin users in those without HF. In HF patients, less selective SGLT2 inhibitors showed superior CV composite outcomes, even surpassing the performance of highly selective SGLT2 inhibitors.Trial registration: PROSPERO [CRD42022361906].ConclusionsOur network meta-analysis revealed that empagliflozin users with diabetes experienced a lower risk of dying from any cause than those using dapagliflozin. Additionally, canagliflozin users demonstrated a reduced risk of cardiovascular death or HHF compared to dapagliflozin users in those without HF. In HF patients, less selective SGLT2 inhibitors showed superior CV composite outcomes, even surpassing the performance of highly selective SGLT2 inhibitors.Trial registration: PROSPERO [CRD42022361906].
    關聯: Cardiovascular Diabetology, v.22, n.1, Article 290
    Appears in Collections:[保健營養系(所) ] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML97View/Open
    s12933-023-02035-8.pdf2079KbAdobe PDF35View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback